Kornimate/medical-research-clean huggingface dataset:
prognostic factors affecting survival of gastric gist

Conditions: Gastric GIST

Summary: gastrointestinal stromal tumor (gist) is the most common non-epithelial mesenchymal tumor of the gastrointestinal tract. surgical treatment is the only curative therapy for primary localized gist. this study aimed to identify the clinicopathological characteristics of gastric gists and to study the predictive factors for recurrence in tunisian patients.

the prognosis of gastric gist depends on various tumor factors with the most important being the mitotic index and tumor necrosis. imatinib therapy has revolutionized the treatment of advanced gist. they have been the subject of much controversy in terms of their histogenesis, classification, treatment and prognosis. gists are histologically similar to smooth muscle and nerve tumors such as leiomyomas, leiomyosarcomas or schwannomas. currently they are well characterized with the recent discovery of the c-kit gene mutation and the expression by tumor cells of the c-kit protein. moreover, the discovery of this receptor is at the origin of the introduction of a "targeted therapy": an anti-tyrosine kinase molecule having revolutionized the therapeutic management of these tumors. however, the standard curative treatment of gist remains complete surgical resection with negative margin from the tumor.

Eligibility criteria:
inclusion criteria: patient having gastric gist - exclusion criteria: * patient operated for other gastric tumors
resilient, empowered, active living: real diabetes study

Conditions: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Summary: this three-year award will pilot-test an innovative intervention, resilient, empowered, active living with diabetes (real), targeting underserved minority young adults with poorly-controlled diabetes. the individually tailored, community-based intervention merges findings of an in-depth needs assessment, principles of an evidence-based occupational therapy intervention (lifestyle redesign®) and evidence-based diabetes self-management strategies. a proof-of-concept study demonstrated that real is feasible to implement, acceptable to young adults with type 1 diabetes and type 2 diabetes, and has potential to produce positive changes in diabetes self-care and glycemic control. the study will randomize 80 young adults with diabetes to receive either the six-month real intervention or an attention control condition. blinded data collectors will assess glycemic control, diabetes self-care behaviors and quality of life outcomes, as well as potential intervention mediators, before and after the six-month intervention. it is anticipated that findings from this pilot study will be used to inform a large-scale randomized controlled trial of the real intervention. the study's specific aims and hypotheses are as follows: aim 1. determine the intervention's efficacy for the primary outcomes: glycemic control and diabetes self-care. hypothesis: at 6 months (immediately following the intervention), intervention group participants will demonstrate improvements in a1c and diabetes self-care as compared to control group participants. aim 2. conduct exploratory analyses of the intervention's impact on secondary outcomes and potential mediating mechanisms (to inform power estimates for a large-scale rct). hypothesis 1: at 6 months, intervention group participants will demonstrate improvements in secondary outcomes: diabetes-related stress and quality of life, depression, and life satisfaction as compared to control group participants. hypothesis 2: at 6 months, intervention group participants will demonstrate improvements in potential mediators of the intervention: habit strength, problem solving, activity participation, self-efficacy and diabetes knowledge as compared to baseline. aim 3. conduct a process evaluation utilizing mixed methods to evaluate and refine intervention delivery (e.g. treatment fidelity, patient satisfaction) and study procedures (e.g. recruitment, retention, testing protocol).


Eligibility criteria:
inclusion criteria: * diagnosed with type 1 or type 2 diabetes mellitus for a minimum of 12 months * most recent a1c ≥8.0% * fluent in english or spanish * reachable by telephone or text message * willing to participate in study activities * reside in los angeles county with no plans to relocate exclusion criteria: * pregnant or planning to become pregnant * cognitive impairment or severe disability limiting life expectancy * participated in lifestyle intervention targeting diabetes within past 12 months * participated in formative research related to intervention development.
transcutaneous spinal stimulation for children and youth with spina bifida

Conditions: Myelomeningocele; Spina Bifida

Summary: a study to use transcutaneous spinal cord stimulation to characterize sensorimotor deficits in a pediatric population of individuals with spina bifida.

the study's goals involve understanding how transcutaneous stimulation affects motor deficits across three dimensions; weakness, coordination, and spasticity. this will be investigated by an electrophysiological characterization lower-extremity deficits, using ts to interrogate neuromotor topography and connectivity of the spinal cord to specific muscles. these evaluations will enable a unique patient-specific understanding of the electrophysiological mechanisms underlying motor deficits. furthermore, these evaluations will assess the therapeutic potential of a novel closed-loop ts plasticity induction protocol to strengthen weakened muscles in a pediatric sb population.

Eligibility criteria:
inclusion criteria * congenital diagnosis of myelomeningocele (mmc) * able to follow verbal commands or instructions. * if female and able to become pregnant, must be willing to use medically-acceptable method of contraception during study participation. exclusion criteria * severe cognitive deficits demonstrating inability to communicate needs * gaping, weeping, or unhealed open wounds * unhealed fractures on load bearing bones * history of osteoporosis * history of implanted electronic devices at the stimulation location(e.g. deep brain stimulator, cardiac pacemaker, diaphragmatic pacer, baclofen pumps, insulin pumps, etc.) * pregnancy * epilepsy * history of seizure * ongoing infections (currently being treated or are symptomatic) * any illness or condition which, based on the research team's assessment, will compromise the patient's ability to comply with the protocol, patient safety, or the validity of the data collected during this study.
increased liver stiffness: a study of acoustic radiation force impulse (arfi) elastography

Conditions: Liver Fibroses

Summary: the goal of this study is to determine if ultrasound tools can be used to detect liver stiffness. acoustic radiation force impulse (arfi) elastography and backscatter will be used to see if they can detect liver stiffness in different populations of patients with liver disease. the study is measuring liver stiffness in pediatric patients aged 2-5 years. patients either have had a fontan cardiac surgery or have liver disease. ultrasound scanning takes images of the liver and has much lower risks for patients. arfi elastography and other tools can be used to measure liver stiffness.

if patients have liver congestion, reversing it could prevent liver fibrosis, which cannot be treated. liver fibrosis has serious health risks and is associated with a higher chance of developing liver cancer later in life. subjects from two patient populations will be enrolled in order to test ultrasound technologies. a total of 30 subjects between 2-5 years of age will be enrolled. 1. 15 children with increased liver stiffness due to the fontan operation 2. 15 children with increased liver stiffness caused by biliary atresia.

Eligibility criteria:
inclusion criteria: * patients aged 2-5 years * children who are scheduled to have a stage 3 fontan cardiac operation (arm 1) and children who have chronic liver disease caused by biliary atresia (arm 2) * patient must be receiving care at the university of michigan cs mott children's hospital * parent/guardian must be willing to sign the study consent form exclusion criteria: * for arm 1 subjects: pre-existing evidence of chronic liver disease (as defined by chronic elevation (over 4 weeks) of alanine aminotransferase (alt), aspartate aminotransferase (ast), or conjugated bilirubin to greater than two times the upper limit of normal * for arm 1 subjects: evidence of overt liver nodularity by conventional us imaging or evidence of portal vein or hepatic vein thrombosis (clots) by us doppler exam

Keywords: liver stiffness fontan
a phase ii study with low-dose recombinant human il-2 for the treatment of primary sjögren's syndrome

Conditions: Primary Sjögren's Syndrome

Summary: primary sjögren's syndrome (pss) is an autoimmune disorder characterized by keratoconjunctivitis sicca and xerostomia. in addition, various extraglandular manifestations may develop. several immunomodulating agents have been attempted in the treatment of pss without achieving satisfactory results. currently, there is no approved systemic treatment for pss. dysfunction of regulatory t (treg) cells has been detected in diverse autoimmune diseases, which can be promoted by interleukin-2 (il-2). the investigators hypothesized that low-dose il-2 could be a novel therapy in active pss patients. this clinical study will test the efficacy and safety of low dose il-2 treatment in pss. the investigators perform a single-centre, double-blind pilot trial with hril-2 in pss. the investigators evaluate the effectiveness and safeness of low-dose hril-2 for primary sjögren's syndrome by randomized controlled study (hril-2 (n = 30) versus placebo group (n = 30)).

each pss patients (n=60) with scores\>=6 on essdai received low-dose il-2 or placebo (active group: placebo group =1:1, 1 million units every other day subcutaneously (hril-2 1x 106, ip, qod) for a period of 14 days. after a 14-day rest, another cycle started) for 3 cycles. the end points were safety, clinical and immunologic response.

Eligibility criteria:
inclusion criteria: * diagnosis of a primary sjögren´s syndrome * essdai score ≥ 6 * liver values above 1,5 uln * stable low dose systemic use of glucocorticoids（\<=7.5mg） in the last 4 weeks before begin with study medication exclusion criteria: * secondary sjögren's syndrome * pre-treatment with cyclosporine a * receiving cyclosphosphamide, corticosteroid bolus with dose over 1 mg/kg, rituximab, belimumab, other immunosuppressives * infection * neoplasia * relevant cardiac, pulmonary, neurologic or psychiatric disease * life-vaccination within 4 weeks before begin with study medication * pregnant or breast-feeding * weight under 45kg or more than 80kg
influence of bariatric surgery on serum levels of 26rfa

Conditions: Diabetes; Obesity

Summary: the 26rfa was recently discovered in the hypothalamus. in rodents it seems to be related to glucose metabolism and obesity. however, no data exists in obese patients or in patients with diabetes. thus, the investigators planned to dose 26rfa level in obese patients before and after a sleeve gastrectomy in order to study the effect of a weight loss on its levels. the investigators will also dose 26rfa concentrations in obese patients with type 2 diabetes and in healthy volunteers with normal weight. comparison of these different groups will permit us to better understand the 26rfa involvement in glucose concentration regulation and in obesity.

the 26rfa is an orexigenic neuropeptide of the rfamides family, localized in two hypothalamic nuclei. its increase induced obesity and it is elevated in obese rodents. in addition, in human, it is elevated in anorexic patients. however, no data exists in obese patients or in patients with diabetes. thus, the investigators planned to measure 26rfa level in obese patients before and after a sleeve gastrectomy in order to study the effect of a weight loss on its levels. the investigators will also dose 26rfa concentrations in obese patients with type 2 diabetes and in healthy volunteers with normal weight. comparison of these different groups will permit us to better understand the 26rfa involvement in glucose concentration regulation and in obesity. the investigators will also measure other hormones known to have a major role in glucose metabolism and obesity (ie. insulin, adiponectin). a meal test will be given to the volunteers in order to study the kinetics' of these molecules during and after food intake.

Eligibility criteria:
1. patients : 1. inclusion criteria: * obese patients (with or without type 2 diabetes) with a planned sleeve gastrectomy 2. exclusion criteria: * hba1c \>11 %. 2. healthy volunteers : 1. inclusion criteria: * 20 ≤ bmi ≤ 25 kg/m², * with no treatment that may influence the glycemic control, * normal electrocardiogram, * no disturbance of the following blood tests: cbc, serum electrolytes, glucose, * negative serology of hiv, hepatitis b and c, * does not participate at another clinical trial in the last 3 months 2. exclusion criteria: * severe medical or surgical history, particularly endocrine or cardiac, * oedema syndrome, * hypertension.

Keywords: 26rfa sleeve gastrectomy diabetes obesity
capsule endoscopy in obscure gi bleeding

Conditions: Obscure Gastrointestinal Bleeding

Summary: the purpose of this study is to conduct a cost-effectiveness analysis of wireless capsule endoscopy in the investigation of patients with overt obscure gastrointestinal bleeding. to inform this analysis, a randomized controlled trial of capsule endoscopy compared with standard care will be conducted

the purpose of this study is to conduct a cost-effectiveness analysis of wireless capsule endoscopy in the investigation of patients with overt obscure gastrointestinal bleeding. to inform this analysis, a randomized controlled trial of capsule endoscopy compared with standard care will be conducted. patients randomized 1:1.

Eligibility criteria:
inclusion criteria: 1. age 18 or older 2. obscure overt gi bleeding 3. no cause for bleeding found on gastroscopy and colonoscopy within 1 week of bleeding exclusion criteria: 1. known or suspected swallowing disorders 2. known or suspected small bowel obstruction 3. multiple comorbidities precluding surgery 4. patients with implantable electromagnetic devices 5. pregnant women
effectiveness of dry needling for improving gait in the patient with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: multiple sclerosis (ms) is a chronic, inflammatory, autoimmune disease characterized by the appearance of lesions, characterized by heterogeneity in its pathological, clinical and radiological presentation. it has a significant socioeconomic impact, affecting interpersonal relationships and causing a significant reduction in quality of life. patients with ms suffer from a series of symptoms (ocular, spasticity, cerebellar, sensory, fatigue, depression) that may be independent of the course of the disease and their management significantly influences quality of life and also requires multidisciplinary therapeutic measures. physiotherapy and occupational therapy techniques are essential to reduce spasticity and prevent complications derived from it. amongst physiotherapy techniques, we can find minimally invasive techniques such as dry needling which uses a fine filiform needle to penetrate the skin and mechanically break the myofascial trigger points, charactewrized by abnomral/pathological electrical activity. there have been previous studies with dry needling in stroke patients which have shown improvements in gait, but its effectiveness in other populations such as multiple sclerosis is still unclear. in addition, dry needling has proven to be a cost-effective treatment for spasticity in patients with chronic and subacute stroke and could be an alternative to other pharmacological treatments, although more studies are necessary to compare both the effectiveness and the cost-effectiveness . recent studies carried out in patients with multiple sclerosis suggest that dry needling can improve mobility and gait speed. the main objective of the study is to analyze the effect of the application of a single session of dry needling in the lower limbs on the gait of patients with multiple sclerosis. a prospective randomized parallel group clinical trial with blinded outcome assessment will be conducted. participants will be recruited from the hospital universitario de canarias.


Eligibility criteria:
inclusion criteria: 1. having been diagnosed with multiple sclerosis in a period of more than two years before the study starts 2. participate voluntarily and sign the informed consent. 3. suffering from some type of hypertonia or spasticity in mmii that makes walking difficult, measured with expanded disability status scale\>2 (pyramidal section \>2) 4. age from 18 to 60 years old. 5. not having phobia of needles. exclusion criteria: 1. not signing the informed consent. 2. having a phobia of needles. 3. presenting an outbreak at the start of the study or having presented any outbreak up to two months before the start of the study.
effectiveness of niclosamide as add-on therapy to the standard of care measures in covid-19 management

Conditions: Covid-19; SARS Pneumonia

Summary: assessment of the effectiveness of niclosamide as add on therapy to the standard of care measures in covid-19 management in a randomized controlled clinical trial

protocol of therapy niclosamaide add on group * ncs 2 grams orally loading dose chewable then 1g every 8 hours in the first day, then on the 2nd day 1g x3 for 7 days. \[ this means only in the first day 4 gm/d then on the second day 3g/d in 3 divided doses for 7 days\] * if the participant requires mechanical ventilation over the course of the study, ngt may be administered via nasogastric (ng) or orogastric (og) tube and, if possible, should be administered with a scheduled nasogastric (ng) or orogastric (og) feeding. control group the patients in this group will receive only standard care which will include all or some of the following, according to the clinical condition of each patient: * acetaminophen 500mg on need * vitamin c 1000mg twice/ day * zinc 75-125 mg/day * vitamin d3 5000iu/day * azithromycin 250mg/day for 5 days * oxygen therapy/ c-pap if needed * dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed * mechanical ventilation, if needed

Eligibility criteria:
inclusion criteria: 1. patients with age above 18 years and of any gender. 2. definite diagnosis of covid-19 according to the who classification criteria ( 18). 3. patients symptomatic for no more than three days for mild-moderate cases, no more than two days after being severe cases, and no more than one day after being critical cases. 4. understands and agrees to comply with planned study procedures. exclusion criteria: 1. patients refuse to enrol in the study 2. patients with hypersensitivity or severe adverse effects to niclosamide 3. renal impairment 4. hepatic impairment 5. pregnancy or a desire to become pregnant 6. breast feeding

Keywords: niclosamide covid-19
ct-p13 (infliximab) subcutaneous administration in patients with moderately to severely active crohn's disease (liberty-cd)

Conditions: Crohn's Disease

Summary: this is phase 3, randomized, placebo-controlled study to demonstrate superiority of ct-p13 sc over placebo sc in patients with moderately to severely active crohn's disease


Eligibility criteria:
inclusion criteria: * patient is male or female aged 18 to 75 years, inclusive. * patient who has moderately to severely active cd with a score on the cdai of 220 to 450 points exclusion criteria: * patient who has previously received either a tnfα inhibitor or biological agent within 5 half-lives * patient who has previously demonstrated inadequate response or intolerance to tnfα inhibitors for the treatment of cd.
a study of the effect of incb013739 on cortisone reducing enzyme activity in obese people predisposed to diabetes

Conditions: Insulin Resistance; Obesity

Summary: the purpose of this study is to determine whether the investigational drug incb013739 has an effect on systemic and adipose tissue 11-hsd1 activity in obese, insulin resistant subjects.

"proprietary information: exploratory (non-confirmatory) trial".

Eligibility criteria:
inclusion criteria: * male and female subjects between 18 years and 65 years of age. * bmi between 30 and 42 kg/m2, inclusive. * fpg \<126 mg/dl exclusion criteria: * meet criteria for diagnosis of diabetes mellitus at the screening evaluation, female subjects with a history of gestational diabetes are permitted. * are receiving oral antidiabetic agents within the 3 months prior to screening.
work, weight, and wellness program: the 3w program

Conditions: Cardiovascular Diseases; Heart Diseases; Obesity

Summary: the purpose of this study is to increase physical activity, improve diet, and reduce obesity of hotel employees.

background: in hawaii, as in many other states, tourism is a large industry. most hotel jobs require little education or training, and hotels employ large numbers of persons and immigrants with low socioeconomic status. hawaii, with the world's most ethnically diverse population, has high rates of obesity and diabetes, particularly among those of polynesian ancestry (about 20-22% of the population). this study will include a comprehensive lifestyle change program delivered through worksites in partnership with a large health care system. design narrative: thirty-one hotels employing 11,000 persons on the island of oahu are pair-matched. one member of each pair is assigned to a high intensity intervention and the other to a low intensity intervention. both interventions are intended to reduce bmi through an emphasis on a healthy diet and increased physical activity. all employees are assessed annually for three consecutive years. the assessment includes a survey on lifestyle habits, stage of change, and attitudes toward weight, as well as measurement of bmi. the high intensity intervention hotels receive the following: 1) environmental changes to support lifestyle change and obesity control; 2) worksite based groups that offer state-of-the-art behavioral interventions; and 3) after-hours "re-invent yourself" groups designed for persons who want to lose at least 25 pounds and are highly committed to doing it. these interventions incorporate all the elements that produce sustained weight loss and an innovative decision tutorial based on decision theory. the primary outcome is the mean difference between hotels in the high intensity and low intensity interventions in change in bmi from baseline to 12 and 24 months. secondary outcomes address effects of the intervention on ethnic and occupational subgroups stage of change, absentee days, and worker compensation claims.

Eligibility criteria:
inclusion criteria: * employed at the hotel exclusion criteria: * unable to read english, korean, or chinese